General Electric beats recent earnings estimates, focuses on healthcare and energy R&D

Medical and healthcare technologies were again prevalent when taking a survey of GE patent applications recently published by the USPTO. Techniques for determining a better course of treatment when dealing with cancer are described within U.S. Patent Application No. 20150198599, filed under the title TLE3 as a Marker for Chemotherapy. The patent application would protect a method of identifying a breast cancer that will not respond favorably to a chemotherapy treatment that includes either taxane or a taxane derivative; the method involves performing immunohistochemical staining for TLE3 polypeptide on a cancer sample. This technology enables a more effective process of selecting chemotherapies to administer to a patient, especially when the therapy in question is paclitaxel, which carries adverse side effects.